Please login to the form below

Not currently logged in
Email:
Password:

statutory medicines

This page shows the latest statutory medicines news and features for those working in and with pharma, biotech and healthcare.

No further price cut for non-PPRS drugs in UK

No further price cut for non-PPRS drugs in UK

But industry concerned over long-term plan for statutory medicines on the NHS. ... The DH announced in November 2013 that it would reduce the cost of these statutory medicines by 15% as part of wider drug pricing negotiations and there were concerns that

Latest news

  • ABPI Code updates come into effect ABPI Code updates come into effect

    There is also a grace period for the revised statutory scheme, which covers medicines that pharma companies choose to exclude from the voluntary, but more well-used. ... medicines). Bookings for these exams will be through a new website: http://exams.abpi

  • NHS medicine spend to remain flat for two years NHS medicine spend to remain flat for two years

    to face a price cut on branded medicines to stick to the revised budget. ... In addition to the PPRS announcement, the DH also published details of its plans for statutory medicines - branded drugs sold by companies who do not sign up to the voluntary

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Brexit: can pharma 'take back control' of the narrative? Brexit: can pharma 'take back control' of the narrative?

    For example the sector has continued to see UK patients gaining slower and lower access to innovative medicines than other EU countries. ... Another example is the recent consultation on the Statutory Scheme for branded medicines, which seems to directly

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics